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The mechanistic target of rapamycin (mTOR) path-
way serves as a key sensor of cellular-energetic
state and functions to maintain tissue homeostasis.
Hyperactivation of themTOR pathway impairs hema-
topoietic stem cell (HSC) function and is associated
with leukemogenesis. However, the roles of the
unique mTOR complexes (mTORCs) in hematopoi-
esis and leukemogenesis have not been adequately
elucidated. We deleted the mTORC1 component,
regulatory-associated protein of mTOR (Raptor), in
mouse HSCs and its loss causes a nonlethal pheno-
type characterized by pancytopenia, splenomegaly,
and the accumulation of monocytoid cells. Further-
more, Raptor is required for HSC regeneration, and
plays largely nonredundant roles with rapamycin-
insensitive companion of mTOR (Rictor) in these
processes. Ablation of Raptor also significantly
extends survival of mice in models of leukemogen-
esis evoked by Pten deficiency. These data delineate
critical roles for mTORC1 in hematopoietic function
and leukemogenesis and inform clinical strategies
based on chronic mTORC1 inhibition.
INTRODUCTION
mTOR is a serine/threonine(Ser/Thr)-protein kinase that has
been implicated in regulating key processes in hematopoiesis
(Warr et al., 2011). The mTOR pathway is activated under condi-
tions of favorable nutrient availability and directly regulates
several downstreammetabolic processes, such as mRNA trans-
lation, lipid biosynthesis, autophagy, and mitochondrial biogen-Cell Sesis. mTOR exists in two independent multiprotein-containing
complexes that have distinct functions in embryonic develop-
ment and in adult tissue. mTORC1 and mTORC2 are defined
by the scaffolding/substrate-guiding proteins Raptor and Rictor,
respectively (Laplante and Sabatini, 2012).
Perturbation of the mTOR pathway in adult HSCs of mice,
either by the introduction of loss-of-function alleles of Pten or
Tsc1 (both negative regulators of mTOR [Laplante and Sabatini,
2012]) or gain-of-function mutations in mTOR activators RHEB2
or AKT, results in HSC cycling and depletion of long-term (LT)
reconstituting activity (Yilmaz et al., 2006; Zhang et al., 2006;
Chen et al., 2008; Gan et al., 2008; Campbell et al., 2009; Kha-
ras et al., 2010). Chronic mTOR activation can evoke myelopro-
liferative neoplasms (MPN), and in some cases acute leuke-
mias, suggesting a differential requirement for mTOR between
HSCs and leukemia stem cells (LSCs). Furthermore, pharmaco-
logical inhibition of mTOR with rapamycin can restore HSC
activity and/or deplete LSC function in these models. These
studies strongly implicate a role for chronic mTOR activity in
HSC and LSC functions, but do not directly address the
required roles of the individual mTORCs in these systems. In
particular, it is now appreciated that rapamycin is only a partial
mTORC1 antagonist (Choo et al., 2008; Hsu et al., 2011; Yu
et al., 2011) and can inhibit mTORC2 activity in some cell types
(Sarbassov et al., 2006). As ATP-competitive inhibitors of
mTOR have recently been demonstrated to have more potent
antileukemic activity than rapamycin in leukemias (Janes
et al., 2010), knowledge of which mTORC to target to enhance
therapeutic index would be of value in developing novel thera-
peutic interventions. To determine the roles of the mTORCs in
hematopoiesis and leukemogenesis, we utilized mice contain-
ing conditional loss-of-function alleles for Raptor and Rictor.
We observe that Raptor is required for HSC regeneration under
stress conditions while not absolutely required during homeo-
stasis, and that Raptor and Rictor play largely nonredundant
roles in these processes. Of note, loss of Raptor prolongstem Cell 11, 429–439, September 7, 2012 ª2012 Elsevier Inc. 429
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deficiency. These data clarify the roles of the mTORCs in
benign and malignant hematopoiesis, while indicating potential
deleterious responses due to chronic mTORC1 inhibition in the
hematopoietic system.
RESULTS
Deletion of Raptor in Hematopoietic Stem and
Progenitor Cells Ablates mTORC1 Activity
We investigated the effects of mTORC1 loss in hematopoiesis
by utilizing mice containing loxP sites flanking (floxed [Fl])
exon 6 of the Raptor gene, which upon Cre recombinase
expression produce null Raptor alleles (Sengupta et al., 2010;
Peterson et al., 2011). We conditionally deleted Raptor alleles
through use of interferon-inducible transgenic Mx1Cre mice,
in which recombination is induced upon receiving administra-
tion of polyinosinic-polycytidylic acid (pIpC) (Ku¨hn et al.,
1995). Injection of pIpC into 4- to 8-week-old RaptorFl/+, MxCre
or RaptorFl/Fl, MxCre mice resulted in efficient deletion of
Raptor allele(s) and diminished mRNA and protein expression
compared with controls (Figures S1A–S1D available online
and data not shown). Deletion of Raptor in hematopoietic
stem and progenitor cells (HSPCs) led to decreased basal
and Scf-stimulated levels of phospho(p)-4e-bp, as well as
Scf-stimulated levels of pS6 (Figures 1A and 1B; for quantifica-
tion see Figure S1E). Since mTORC1 inhibition can evoke
increased AKT phosphorylation (due to the negation of a nega-
tive feedback loop) (Carracedo and Pandolfi, 2008), we also
examined pAKT levels in HSPCs. Although phosphorylation at
Ser473 was normal in Raptor null HSPCs, phosphorylation of
AKT at Thr308 was slightly prolonged in Scf-stimulated Raptor
null LSK and granulocyte/monocyte progenitors and common
myeloid progenitors (GMPs/CMPs) (Figure 1B). Strikingly, rela-
tive basal levels of pAKT at either site in the more mature
LinSca-1c-Kit cells were markedly elevated in Raptor null
cells, indicating cell type specificity in the mTORC1-PI3K feed-
back loop in hematopoietic cells (Figure 1B). Levels of pERK
were not different between control and Raptor-deleted HSPCs,
indicating that Raptor deletion does not disrupt all c-Kit
signaling (Figure 1B).Figure 1. Deletion of Raptor Ablates mTORC1 Activity and Leads to H
(A) Representative flow-cytometry plots of sorted Lin PI cells postfixation and p
(/) mice (Lin PI Sca-1+c-Kit+ [LSK], Lin PI Sca-1c-Kit+[LK], Lin PI Sca-
Sca-1c-Kit [L S K]).
(B) Flow cytometry was performed on sorted LinPI cells from pIpC-treatedRapt
20 ng/ml of Scf for the indicated time points in minutes (mins), and these were the
maximal value on the y axis), and for quantification see Figure S1E (*p < 0.05 rel
(C) Quantification of CD48/CD150/CD34/Flt3/LSK subsets from BM and spleen (D
(n = 5 +/+, n = 6 /.) For gating see Figure S1N.
(E) Quantification of immunophenotypic HPC subsets from mice described in (C
defined as in Pronk et al. (2007).
(F) Colony-forming cell (CFC) formation from pIpC-treated Raptor Fl/Fl (+/+) and R
(G) Assessment of EdU incorporation in cells from pIpC-treated Raptor Fl/Fl (+/+)
(H) Ho 33342/Ki67 staining from the indicated FACS-sorted LSK populations or wh
Ki67Hi), and SG2M (>2N DNA-Ki67
Hi) are shown (n = 3).
(I) Ho 33342/Pyronin Y in the indicated surface-stained populations of the indica
(J) Heat-map of metabolite measurements from pIpC-treated Raptor Fl/Fl (WT [1–
All data are expressed as mean or mean ± SEM (*p < 0.05, n.s. p > 0.05).
Cell SmTORC1 Regulates Differentiation Along Multiple
Hematopoietic Lineages
Raptor null mice were viable, surviving at least 20 months post-
pIpC and containing predominately deleted alleles (data not
shown). However, within 1 month of deletion, 100% of mice
developed a persistent and rapid pancytopenia, splenomegaly
with extramedullary hematopoiesis and disrupted splenic archi-
tecture, and decreased thymic mass (Figures S1F, S1G, S1K,
and S1L and data not shown). Despite the pancytopenia,
Raptor-deleted bone marrow (BM) maintained BM cellularity
(Figures S1G and S1K). However, Raptor-deleted BM did show
signs of defective hematopoiesis with emergence of monocytoid
features (Figures S1G, S1H, and S1I), but without evidence of
dysplasia or progression to leukemia in old age (data not shown).
Raptor loss leads to an accumulation ofMac-1+Gr-1Mid/Lo mono-
cytes as early as 2 weeks and persisting to at least 5–7 months
postdeletion (Figures S1H–S1J and S1M). Raptor deletion
resulted in increased levels of B220+IgMCD43+ proB cells in
the BM and decreased levels of B220+IgMloIgDHi mature B cells
in spleen (Figures S1H, S1I, and S1M and data not shown).
Finally, Raptor loss perturbed erythroblast frequencies in
the BM and spleen (Figures S1H and S1I). Deletion of Raptor
alleles via tamoxifen administration in RaptorFl/Fl mice
expressing aUBIQUITIN C promoter-driven tamoxifen-inducible
Cre-estrogen receptor (Cre-ER) (Ruzankin et al., 1997) also led to
monocyte expansion (Figure S1M and data not shown), suggest-
ing that the effects observed in the Mx-Cre model were not due
to interferon responses.
Ablation of Raptor Expands LSK Subsets and Mobilizes
HSPCs
Raptor loss evoked a rapid (within 2 weeks), sustained
(5–7 months), and pIpC-independent increase in the frequency
of several LSK subsets (Figures 1C and 1D and Figures S1N
and S1O). In the LT-HSC-enriched Flt3CD34LSK subset
(Osawa et al., 1996; Christensen and Weissman, 2001; Yang
et al., 1995) Raptor loss increased the frequency of both BM
CD48+CD150+, and CD48+CD150 cells, while CD48CD150+
Flt3CD34-LT-HSCs (Kiel et al., 2005; Morita et al., 2010)
were largely unaffected (Figures 1C and 1D). In the short-
term HSC (ST-HSC)-enriched Flt3CD34+LSK subset, RaptorSPC Perturbations
ostpermeabilization from pIpC-treated Raptor Fl/Fl (+/+) and Raptor Fl/Fl, Mx-Cre
1c-Kit+CD34+ [GMP/CMP], Lin PI Sca-1c-Kit+CD34 [MEP], and Lin PI
or Fl/Fl (+/+) andRaptor Fl/Fl, Mx-Cre (/) mice that were stimulated ex vivowith
n processed for flow cytometry. Representative histograms are shown (percent
ative to unstimulated +/+ controls).
) of Raptor Fl/Fl (+/+) and Raptor Fl/Fl, Mx-Cre (/) mice 5–7 months post-pIpc.
), from BM (left panel), and from spleen (right panel). Immunophenotypes are
aptor Fl/Fl, Mx-Cre (/) mouse BM and spleen cells. (n = 3–4.)
and Raptor Fl/Fl, Mx-Cre (/) mice. (n = 3.)
ole BM (WBM) and pIpC-treated genotypes. G0 (2N DNA-Ki67
Lo), G1 (2N DNA-
ted genotypes (as in B) by flow cytometry). HoLo = 2N DNA. (n = 8–9.)
3]) and Raptor Fl/Fl, Mx-Cre (KO [4–6]) LSK cells. (p < 0.057, citrate p = 0.077.)
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Figure 2. Raptor Is Required for HSC Regeneration in a Cell Autonomous Manner
(A) 83 105 whole BM cells from pIpC-treated Raptor Fl/Fl (+/+) or Raptor Fl/Fl, Mx-Cre (/) mice (both CD45.2+) were transplanted into lethally irradiated CD45.1
mice and survival was monitored. Numbers of recipient mice are indicated (left panel). (p value was derived by log-rank test). BM from surviving mice was
analyzed for CD45.2 cell contribution to the CD34Flt3LSK pool 20 weeks post-pIpC (n = 3) (right panel).
(B) BM cells from Raptor Fl/Fl (+/+) and Raptor Fl/Fl, Mx-Cre (/) mice, 6 weeks post-pIpC treatment (both CD45.2+), were mixed at the indicated ratios with
CD45.1+ BM cells and transplanted into lethally irradiated CD45.1 recipients. Percentage of CD45.2+ cells in PB is shown over time (n = 5) (left panel). Twenty-two
weeks posttransplantation the percentage of CD45.2+ CD34LSK cells in BM was assessed (n = 5) (right panel).
(C) FACS-sorted DiD-labeled LSK-CD48CD150+ from pIpC-treatedRaptor Fl/Fl (+/+) andRaptor Fl/Fl, Mx-Cre (/) mice were transplanted into lethally irradiated
Col2.3GFP mice, and 24 hr later live imaging was performed to assess relative distance of HSPCs to osteoblasts. Shown are results from two independent
experiments performed with 5,000–10,000 HSPCs.
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CD48+CD150+, CD48+CD150 cells, as well as an increase in
CD48+CD150+-Flt3CD34+ LSK cells in the spleen (Figures
1C and 1D). Raptor deletion led to an expansion of several
splenic Linc-Kit+-Sca-1-(LK) subsets (Figure 1E), consistent
with increased splenic LSK cells and extramedullary hematopoi-
esis. While Raptor deletion did not affect BM progenitor frequen-
cies, ex vivo colony-forming activity was severely compromised,
forming mostly small irregular colonies in complete-cytokine
media, which was also observed with total splenocytes
(Figure 1F).
Raptor Loss Affects the Cell Cycle and Induces
Metabolic and Gene Expression Alterations in HSPCs
To investigate the effects of Raptor loss on HSPC cell cycle,
5-ethynyl-20-deoxyuridine (EdU) incorporation 2 days postinjec-
tion was assessed in HSPCs. LSK subtypes as well as LK cells
null for Raptor incorporated higher levels of EdU (Figure 1G).
Furthermore, Raptor-deleted ST-HSCs were more likely to be
in the G1 phase of the cell cycle than controls (Figure 1H).
However, Raptor-deleted LT-HSCs did not show steady-state
cell cycle differences, and neither did Flt3+CD34+LSKs (Fig-
ure 1H). Moreover, whole BM cells from Raptor null mice were
in the G0 phase of the cell cycle (Figure 1H). We did not detect
differences in either caspase activity or reactive oxygen species
levels due to Raptor loss (data not shown). Raptor-deleted LSK
subsets, as well as LK cells, did show lower levels of RNA (based
on Pyronin Y staining) (Figure 1I). To ascertain other metabolic
perturbations caused by Raptor loss in HSPCs, we performed
metabolite profiling on LSK cells. This analysis revealed elevated
intracellular concentrations of AMP and NADP+ in Raptor null
cells, indicative of effects in energy and redox homeostasis,
respectively, and increased levels of intermediates involved in
lipid metabolism (choline and a-glycerophosphocholine). We
also observed diminished levels of pyridoxal 50-phosphate,
a key cofactor in transamination reactions and other metabolites
involved in nitrogen metabolism (citrulline, ornithine, and gluta-
mate) (Figure 1J).
Finally, we assessed gene expression alterations induced
by Raptor loss in HSPC-enriched Flt3LSK cells. Gene set
enrichment analysis indicated multiple changes in Raptor null
HSPCs, including alterations in known mTOR-regulated path-(D) Two-hundred LT-HSCs or ST-HSCs from pIpC-treated Raptor Fl/Fl (+/+) and
conditions that promote HSC expansion ex vivo. Seven to nine days postcult
experiments performed in duplicate.
(E) 8 3 105 BM cells from non-pIpC-treated Raptor Fl/Fl or Raptor Fl/Fl, Mx-Cre m
posttransplantationmicewere injectedwith three doses of pIpC over 5 days. PB c
indicated time (n = 9–10 recipients).
(F) BM from mice from (E) was analyzed for CD45.2 chimerism in CD34Flt3 LSK
into two CD45.2+ groups, one with low CD45.2 chimerism that retained deletion (G
(n = 4–5.) (See Figure S2C.)
(G) 2.53 105 BMcells from uninducedRaptor Fl/Fl, Mx-Creweremixedwith 2.53 1
to seven weeks posttransplantation one-half of the mice were injected with pIpC
indicated time points. (n = 6–8, left panel.) Recipient BMwas analyzed for CD45.2
panel).
(H) Kaplan-Meier (KM) survival curve from pIpC-treated Raptor Fl/Fl (+/+), n = 10, an
one surviving/mouse had escaped deletion (data not shown) (left panel). (p va
Mx-Cre (/) mice received sublethal irradiation, and shown is the frequency of
All data are expressed as mean or mean ± SEM (*p < 0.05).
Cell Sways or processes such as cholesterol biosynthesis and the
hypoxia inducible factor pathway, as well as potentially novel
mTORC1-regulated pathways (i.e., depletion of NUP98-
HOXA9 target genes) (Table S1). When considered collectively,
these data indicate that under homeostatic conditions,
mTORC1 is not absolutely required for HSC maintenance, but
its loss does lead to HSPC mobilization and evokes significant
cell cycle, metabolic, differentiation, and gene expression
changes.
Raptor Is Required for HSC Function
Posttransplantation
We next assessed the role of Raptor in hematopoietic regenera-
tion by transplanting BM marked by CD45.2+ cells from
RaptorFl/Fl or RaptorFl/Fl, MxCre+ mice treated with pIpC
(+/+ and /, respectively) prior to transplantation into lethally
irradiated congenic CD45.1+ B6.SJL mice, and found that
most mice receiving Raptor null BM did not survive (Figure 2A).
We then transplanted cells as above along with whole BM
marked as CD45.1+ cells from B6.SJL mice into lethally irradi-
ated CD45.1+ B6.SJL mice at 1:1 and 9:1 test:competitor ratios.
Mice transplanted with / cells showed minimal engraftment
beginning as early as 5 weeks posttransplantation (Figure 2B).
We also transplanted splenocytes in the samemanner as above,
and again foundminimal engraftment fromRaptor null cells (data
not shown).
To assess the homing capacity of Raptor null HSPCs, LSK-
CD48CD150+ cells were isolated from pIpC-treated RaptorFl/Fl
or RaptorFl/Fl, MxCre+ mice, labeled with 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindodicarbocyanine (DiD), and transplanted
into mice with GFP-expressing osteoblasts (Col2.3-GFP)
(Lo Celso et al., 2009). By using live in vivo imaging, we did
not observe any obvious defects in homing. Raptor null HSPCs,
however, did localize further from osteoblast cells (Figure 2C).
This could reflect a requirement for mTORC1 in integrating
niche signals correctly. In fact, Raptor null LT-HSCs or ST-HSCs
couldn’t initiate and/or sustain ex vivo cultures in serum-free
conditions containing niche-secreted factors (Zheng et al.,
2011) (Figure 2D). Overexpression of several downstream
mTORC1 effectors, as well as potential novel targets (namely
Hoxa9), could not restore ex vivo growth in the absence of
Raptor.Raptor Fl/Fl, Mx-Cre (/) mice were used to initiate cultures in serum-free
ure the number of cells was enumerated. Data are from three independent
ice were transplanted into lethally irradiated CD45.1 recipients. Five weeks
himerismwas assessed bymeasuring the contribution of CD45.2+ cells over the
fractions 25 weeks post-pIpC. Raptor Fl/Fl, Mx-Cre recipients were separated
roup 1) and one with high CD45.2 chimerism that escaped deletion (Group 2).
05 CD45.1 cells and transplanted into lethally irradiated CD45.1 recipients. Five
as in (D) (+pIpC). Contribution of CD45.2 cells to PB was assessed over the
cell contribution to the CD34Flt3LSK pool 21weeks post-pIpC (n = 6–8) (right
d Raptor Fl/Fl, Mx-Cre (/) (n = 4) mice that received sublethal irradiation. The
lue was derived by log-rank test.) pIpC-treated Raptor Fl/Fl (+/+) and Raptor Fl/Fl,
BM CD150+-LSK cells 10–12 days postirradiation (IR). (n = 4.)
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Regeneration
To examine the cell autonomous phenotypes, we transplanted
BM from non-pIpC-treated RaptorFl/Fl or RaptorFl/Fl, MxCre+
mice (without helper/competitor) into lethally irradiated
CD45.1+ B6.SJLmice, waited5 weeks, and then induced dele-
tion with pIpC. Approximately 1 month post-pIpC treatment,
all mice receiving RaptorFl/Fl, MxCre cells developed leukopenia,
while mice receiving RaptorFl/Fl did not (Figure S2A). Further-
more, CD45.2+ cells from pIpC-treated mice receiving
RaptorFl/Fl, MxCre+ cells were mostly Mac-1+Gr-1Mid/Lo (Fig-
ure S2B). After 16 weeks host CD45.1+ cells began to contribute
substantially to peripheral chimerism only in pIpC-treated mice
receiving RaptorFl/Fl, MxCre+ cells (Figure 2E). We then analyzed
the BM and spleens of transplant recipients and observed that
mice from pIpC-treated RaptorFl/Fl, MxCre+ could be segregated
into two groups. One (Group 1) had maintained relatively low
percentages of CD45.2+ cells in the BM and spleen, and had
retained deleted-Raptor alleles, whereas the other (Group 2)
contained a high percentage of CD45.2+, but contained mostly
floxed Raptor alleles (i.e., they had escaped deletion) (Fig-
ure S2C). This differential chimerism was also observed in
LT-HSC and ST-HSC fractions (Figure 2F), suggesting a cell
autonomous role for Raptor in HSC self-renewal. Finally, we
transplanted BM cells from RaptorFl/Fl, MxCre+ mice with BM
cells from B6.SJL mice at a 1:1 ratio, waited for stable engraft-
ment (5 weeks), and then induced deletion of Raptor alleles
in one-half of the mice. Mice receiving pIpC displayed a steady
reduction in peripheral chimerism, and Raptor null grafts were
outcompeted (Figure 2G).
To assess the regenerative capacity of Raptor null HSCs in
nontransplantation settings, pIpC-treated RaptorFl/Fl (+/+) or
RaptorFl/Fl, MxCre+ (/) mice were treated with a sublethal
dose of irradiation. While all +/+ mice survived this treatment
and showed signs of BM regeneration over time, most /
died rapidly, without signs of normal BM regeneration (Figure 2H
and data not shown). Furthermore, while +/+ LT-HSC enriched
CD150+-LSK cells were reduced by 5.8 ± 1.3-fold relative to
unirradiated mice 10–12 days postirradiation, there was a
16.9 ± 3.7-fold decrease in this population in / mice (p <
0.05) (Figure 2H). Taken together, these data indicate that
Raptor/mTORC1 activity appears to be generally required in
regenerative hematopoietic settings.
Neither mTOR Complex Is Absolutely Required
In Hematopoietic Homeostasis
To determine the role of mTORC2 in adult hematopoiesis, we
utilized mice with a floxed Rictor exon 3 allele (Shiota et al.,
2006) and generated RictorFl/Fl or RictorFl/Fl, MxCre+ animals.
pIpC treatement of RictorFl/Fl, MxCre+ mice ablated mTORC2
activity in HSPC in response to Scf, but did not affect phosphor-
ylation of AKT at Thr308 ormTORC1 activity (Figure 3A). Deletion
ofRictor in the hematopoietic systemwas tolerated and primarily
resulted in diminished peripheral blood (PB) lymphocytes, a
reduction in spleen mass, and a decrease in splenic B220+
IgMLoIgD+ cells (Figures S3A–S3C and data not shown), pheno-
types consistent with loss of PI3K/AKT signaling (Fruman et al.,
1999; Calamito et al., 2010). Rictor loss did not affect HSPC
number by immunophenotype (Figure 3B and data not shown)434 Cell Stem Cell 11, 429–439, September 7, 2012 ª2012 Elsevier Iand did not diminish HSPC chimerism at 30 weeks in a compet-
itive transplant (Figure 3C). However, we did observe that Rictor
null BM contributed to lower levels of PB cells, particularly those
of the lymphoid lineages (Figure 3C and Figure S3D).
Finally, we assessed the requirement of both mTORC1
and mTORC2 in hematopoietic homeostasis by generating
compound RaptorFl/Fl, RictorFl/Fl, MxCre+. pIpC-treatment of
RaptorFl/Fl, RictorFl/Fl, MxCre+ led to reduced phosphorylaton
of both mTORC1 andmTORC2 substrates in HSPCs (Figure 3D).
Compound-deleted mice had phenotypes largely resembling
hematopoietic Raptor deletion, and did not develop BM failure
(Figures 3E and 3F and Figures S3E–S3I and data not shown)
(Figure 3E). Lastly, compound mice retained deleted alleles of
both Raptor and Rictor up to 10 months postdeletion (data not
shown). Taken together, mTORC1 and/or mTORC2 play largely
nonredundant roles in hematopoiesis.
Raptor Deletion Prolongs Survival in Models
of Pten-Loss-Evoked Leukemogenesis
Since hyperactivation of mTOR is observed in many hematolog-
ical malignancies (Chapuis et al., 2010), we asked whether
complete loss of function of mTORC1 could impact leukemo-
genesis in vivo. We utilized PtenFl/Fl, MxCre mice that develop
symptoms of myeloproliferative neoplasm (MPN), can progress
to acute leukemia, and whose leukemias are sensitive to rapa-
mycin (Yilmaz et al., 2006; Zhang et al., 2006). We produced
PtenFl/Fl mice that were Raptor+/+, RaptorFl/+, or RaptorFl/Fl (all
MxCre positive) and induced deletion. Homozygous, but not
heterozygous, Raptor deletion significantly prolonged survival
of Pten null mice, and ameliorated some but not all neoplasia-
associated phenotypes (Figures S4B–S4E). However, homozy-
gous Pten deletion did lead to lethality in the majority of
compound mice (Figure 4A). Surviving doubly-deleted mice dis-
played slightly enlarged spleens and significantly larger livers
relative to induced RaptorFl/Fl, MxCre mice (532 ± 83.8 versus
318 ± 37.72 mg for spleen weights, p < 0.05, and 2.44 ± .347
versus 1.16 ± 0.113 g for liver weights, p < 0.05, n = 4–6). White
blood cell (WBC) liver infiltrates were apparent in some animals,
while some animals displayed large amounts of liver lipid
deposits (data not shown). Efficient deletion in most cells for
both Raptor and Pten alleles was detected (Figure 4B and Fig-
ure S4A). Finally, Raptor loss had no effect on the frequency of
Pten-loss-evoked changes to BMor splenic LSK-CD48CD150+
cells (Figure 4C).
To investigate if these effects were cell autonomous, we trans-
planted PtenFl/Fl, MxCre+ cells that were either RaptorFl/+ or
RaptorFl/Fl (both CD45.2+) along with CD45.1+ helper/competitor
cells at a 2:1 ratio into B6.SJLmice, waited5weeks for engraft-
ment, and then treated themwith pIpC. In this system,mostmice
receiving PtenFl/Fl, MxCre BM develop hematological malignan-
cies, the most prevalent of which is T-acute lymphoblastic
leukemia/lymphoma (T-ALL) (Lee et al., 2010). Heterozygous
deletion of Raptor in this model led to a median survival of
11 weeks post-pIpC, while homozygous deletion of Raptor
only lead to lethality in a few of the transplant recipients (Fig-
ure 4E). Notably, after 22 weeks homozygous deletion of Raptor
lead to reduced chimerism (Figures 4E and 4F). Therefore,
Raptor is required in a cell autonomous manner for efficient
Pten-loss-evoked leukemogenesis.nc.
Figure 3. Rictor Is Required for mTORC2 Activity in HSPC, but Not LT-Hematopoietic, Regeneration
(A) Flow cytometry was performed on sorted LINPI cells from pIpC-treated Rictor Fl/Fl (+/+) and Rictor Fl/Fl, Mx-Cre (/) mice that were treated with Scf for
the indicated time (mins). Shown are data from fixed/permeablized LSK-gated events, and fold change in median fluorescent intensity (MFI) for the indicated
p-protein is shown relative to untreated +/+ cells. (n = 3–4 mice.)
(B) Frequency of BM LSK subsets from Rictor Fl/Fl (+/+) and Rictor Fl/Fl, Mx-Cre (/) mice 4 months post-pIpC treatment. (n = 4–5.)
(C) 53 105 whole BM cells from pIpC-treatedRictor Fl/Fl (+/+) andRictor Fl/Fl, Mx-Cre (/) mice (both CD45.2+) weremixedwith the same amount of CD45.1+ BM
cells and transplanted into lethally irradiated CD45.1 recipients. The percentage of CD45.2+ cells in PB is shown over the indicated time (n = 6–7 recipients).
Panels on the right show the percent contribution of CD45.2+ cells to the indicated BM populations 30 weeks posttransplantation. Data are from one of two
experiments.
(D) The levels of indicated p-proteins were assessed as in (A) in Scf-treated LSK-gated cells from pIpC-treated mice of the indicated genotypes. (n = 3–4mice per
genotype.)
(E) BM cell number (n = 2–9), spleen mass (F) (n = 5–9), and percentage of Mac-1+Gr-1Mid/Lo splenic cells (F, right panel) (n = 3–5) are shown from mice of the
indicated genotype 1–3 months post-pIpC treatment.
All data are expressed as mean ± SEM (*p < 0.05, n.s. p > 0.05).
Cell Stem Cell
mTORC1/Raptor Roles in Hematopoiesis and LeukemiaAlthough it was diminished, we did observe T cell lymphoma/
leukemia development in a minority of Pten/Raptor double
knockouts (that could be transplanted; data not shown). As
mTORC2 is functionally active inRaptor-deleted cells, we sought
to determine the role of mTORC2 in Pten-loss disease in theCell Sabsence of Raptor. We observed the highest levels of AKT phos-
phorylation at Ser473 in Raptor/Pten double homozygous-
deleted LSK cells (Figure 4G). Hyperactivation of AKT should
predictably result in diminished Foxo activity (Guertin et al.,
2006), which has previously been associated with depletiontem Cell 11, 429–439, September 7, 2012 ª2012 Elsevier Inc. 435
Figure 4. Raptor Is Required for Efficient Leukemogenesis Evoked by Pten Loss
(A) KM curve from PtenFl/Fl, MxCre mice of the indicated Raptor genotypes that were treated with pIpC. Number of mice is indicated (*p < 0.05, log-rank test).
(B)Western blots were performedwith BMand spleen extracts frommice of the indicated genotypes6months post-pIpC using the indicated antibodies. Shown
are samples from two individual pIpC-treated Raptor Fl/Fl, PtenFl/Fl, MxCre mice.
(C) The frequency of BM and splenic (D) LSK-CD48CD150+ cells was assessed from mice of the indicated genotypes 2.5 to 5 weeks post-pIpC treatment
(n = 6–10).
(E) 1 3 106 BM cells from non-pIpC-treated mice of the indicated genotypes (CD45.2) were mixed with 5 3 105 CD45.1 cells and transplanted into lethally
irradiatedCD45.1mice. Five and one-half weeks posttransplant mice received three injections of pIpC over six days. Survival (left) and chimerism (right) were then
assessed (n = 4–6, *p < 0.05, log-rank test).
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mTORC1/Raptor Roles in Hematopoiesis and Leukemiaof HSC function (Tothova et al., 2007) as well as impaired leuke-
mogenesis (Sykes et al., 2011). We thus generated RaptorFl/Fl,
RictorFl/Fl, PtenFl/Fl, MxCre+ triple knockout mice and induced
deletion (Figure S4F). However, all triple knockout mice died
relatively rapidly (median survival of 19 days [n = 6] without signs
of BM failure [data not shown]). We next transplanted non-pIpC-
treated BM from RaptorFl/Fl, RictorFl/Fl, PtenFl/Fl, MxCre mice
along with controls (Figure 4H) as above, and induced deletion
5–7 weeks posttransplantation. The additional loss of Rictor (in
theRaptor/Pten double knockout cells) did not lead to any differ-
ences relative to Raptor-deleted Pten-homozygous chimerism
(Figure 4H). Notably, homozygous deletion of Rictor alone did
allow for stable LT PB chimerism and prolonged survival (Fig-
ure 4H and data not shown).DISCUSSION
We found that Raptor/mTORC1 plays critical functions in
HSPCs, hematopoietic differentiation, and leukemogenesis.
Previous work has established chronic mTOR activation as
depleting HSC function. Herein, we identify mTORC1 to be
required for HSC function under regenerative settings. It is likely
then that the level of mTORC1 activity needs to be balanced in
HSCs, whereas either increased or decreased mTORC1 levels
result in diminished capacity for HSC function. As mTOR lies
downstream of several hematopoietic growth factor/cytokine
receptors, this could reflect a particular need for this signaling
axis in self-renewal under regenerative conditions. In fact,
thrombopoietin (Thpo), which partially signals through mTOR,
has been shown to be essential for HSC function (Qian et al.,
2007). Of note, Thpo deficiency evokes similar decreases in
several self-renewal-associatedHoxA genes that are also down-
regulated in Raptor null HSPCs (Table S1). We propose that
mTORC1 enables proper HSC sensing of both niche factors
and cellular energetic state, and that loss of function of mTORC1
leads to imprecise integration of these signals and loss of regen-
erative potential.
While loss of Raptor leads to multiple hematopoietic abnor-
malities, homozygous Raptor deletion in hematopoietic cells is
tolerated in mice, as is complete ablation of both mTORC1 and
mTORC2 activity under homeostatic hematopoietic settings.
We have demonstrated that mTORC1 loss via homozygous
Raptor ablation is sufficient to extend survival in mouse models
of Pten-loss-evoked leukemogenesis in a cell autonomous
manner. Previous results have shown that Pten-loss-evoked
HSC depletion is rapamycin sensitive (Yilmaz et al., 2006). In
contrast, our results show that homozygous deletion of Pten
andRaptor leads to a gradual loss in reconstituting capacity (Fig-
ure 4D). It is possible that rapamycin-sensitive functions of
mTORC1 downstream of Pten loss, perhaps the upregulation
of the p53/p19Arf/p16Ink4a axis, lead to HSC depletion (Lee(F) Chimerism was assessed from surviving mice that received RaptorFl/Fl, Pten
in (E). (n = 4.)
(G) Assessment of p-protein levels in LSK-gated events from Scf-treated LINPI
(H) BM cells frommice of the indicated genotypes (all from PtenFl/Fl, MxCre backgr
is indicated.
All data are expressed as mean or mean ± SEM (*p < 0.05, n.s. p > 0.05).
Cell Set al., 2010), while rapamycin-insensitive functions of mTORC1
are required for HSC regeneration independent of Pten levels.
These rapamycin-sensitive functions of mTORC1 are potentially
downstream of mTORC2 signaling in response to Pten loss. In
fact, Magee et al. (2012) demonstrate that loss of Rictor extends
survival of pIpC-treated PtenFl/Fl, MxCre mice, while also
showing that rapamycin does not affect mTORC2 activity in
HSCs in vivo. Unlike some Raptor-deleted mice in this setting
(MxCre), Rictor deletion was not compatible with acute
leukemia/lymphoma development. Furthermore, like rapamycin
treatment and unlike Raptor deletion, Rictor deletion restores
normal function to Pten-deleted HSCs (Magee et al., 2012).
When these data are taken together, both mTORC1 and
mTORC2 functions appear to be required downstream of Pten
loss in HSC function as well as in leukemogenesis, while
mTORC1 functions appear to be important for HSC regeneration
regardless of Pten status.
This work demonstrates previously uncharacterized functions
of mTORC1 in hematopoiesis and nonredundant hematopoietic
functions of mTORCs, and confirms mTORC1 requirements in
cancers with hyperactivation of the PI3K pathway. This work
also provides mechanistic insight into the role of specific
signaling pathways that control hematopoietic regeneration
and will inform on therapeutic strategies.EXPERIMENTAL PROCEDURES
Mouse Experiments
Mouse strains are detailed in the Supplemental Experimental Procedures.
Deletion of floxed alleles was induced by intraperitoneal (IP) injections of
4- to 8-week-old Mx1Cre mice with 15 mg/g body weight pIpC three times
over 5–6 days, or UBC-cre-ER compound mice with 200 mg/g body weight
Tamoxifen (Sigma, St. Louis, MO) once daily for 3 days. For transplantation
experiments mice received lethal doses of irradiation (two doses at 550 rad
3 hr apart) prior to transplantation of BM cells by retro-orbital injection on
the same day. Complete blood counts were performed on PB samples using
a Hemavet (Drew Scientific, Dallas, TX).
Flow Cytometry
Antibodies utilized for flow cytometry are detailed in the Supplemental Exper-
imental Procedures. Cells were isolated from BM either by flushing long bones
or crushing bones in a mortar and pestle, red blood cells (RBC)s were lysed
with BD Pharmlyse lysis buffer (BD), and cells were passed through 40 or
70 mm nylon cell strainers (BD). BM cells used in sorting experiments were
enriched for Lin cells by being stained with PE-Cy5-conjugated rat anti-
mouse antibodies, followed by being incubatedwith sheep anti-rat Dynabeads
(Invitrogen, Carlsbad, CA) and undergoing cell separation with magnetic
columns. Intracellular flow cytometry was performed as described previously
(Kalaitzidis and Neel, 2008). EdU incorporation was assessed by IP injection of
mice with 60 mg/kg EdU, and incorporation was analyzed in FACS-sorted cell
populations with the Click-iT EdU (Alexa Fluor-647) Assay kit (Invitrogen).
For Ki67/DNA staining, FACS-sorted cells were washed once with PBS,
resuspended in cold 70% ethanol, and left at 20C overnight. Cells were
pelleted, washed once with 0.5% BSA/PBS, and stained with a PE-Cy7-
conjugated antibody to Ki67 (B56 [BD]) and 30 mM Hoechst (Ho) 33342Fl/Fl, MxCre cells from (E), in the indicated cell populations/organs. described
 cells of the indicated genotypes (n = 2–3).
ounds) were transplanted and treated as in (D). Number of transplant recipients
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mTORC1/Raptor Roles in Hematopoiesis and Leukemia(Invitrogen) for 30 min at 20C prior to preparation for flow cytometric
analysis. For DNA/RNA content measurements, BM cells in 10%FBS/IMDM/
50 mg/ml verapamil were incubated with 30 mM Ho 33342 for 45 min at
37C, washed, and stained for surfacemarkers and 3 mg/mL Pyronin Y (Sigma)
for 20 min at 37C. Enumeration of 200 FACS-sorted LT-HSCs or ST-HSCs
grown in 500 ml in wells of 12-well plates, in conditions described previously
(Zheng et al., 2011), was with Countbright Absolute Counting Beads
(Invitrogen).
Gene Expression Analysis
RNA from FACS-sorted cells was isolated with the Arcturus PicoPure RNA
Isolation Kit (Applied Biosystems, Carlsbad, CA). cDNAwas synthesized using
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Quantitative PCR was performed using Taqman probes to murine Gapdh
and Raptor (Mm00712697_m1 spanning exons 5–6 and Mm01242616_g1
spanning exons 8–9). qPCR reactions were run on either Applied Biosystems
7300 or 7500 RT PCRSystems. Details ofmicroarray experiments are supplied
in the Supplemental Experimental Procedures.
Metabolite Profiling
For metabolite profiling BM cells from four mice per genotype were pooled
and used to FACS sort 100,000–150,000 LSK cells (one biological replicate).
Cells were washed with PBS and resuspended in 200 ml of 100% methanol.
Metabolite measurements are from three biological replicates per genotype.
A detailed description of the methods used to obtain raw data is in the Supple-
mental Experimental Procedures.
In Vivo Imaging
In vivo imaging was performed on 5,000–10,000 Vybrant DiD-dye labeled
(Invitrogen) LSK-CD48CD150+ FACS-sorted cells using Col2.3-GFP recip-
ient mice as described previously (Lo Celso et al., 2009) and detailed in the
Supplemental Experimental Procedures.
Statistical Analysis
The statistical significance of differences between population means was
assessed by two-tailed unpaired Student’s t test unless otherwise indicated.ACCESSION NUMBERS
Microarray data have been deposited at the NCBI Gene Expression Omnibus
with accession code GSE32265.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four figures, one table, and
Supplement Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.stem.2012.06.009.
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